CYCN
Income statement / Annual
Last year (2024), Cyclerion Therapeutics, Inc.'s total revenue was $2.00 M,
and the percentage change from the previous year is not available.
In 2024, Cyclerion Therapeutics, Inc.'s net income was -$3.06 M.
See Cyclerion Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.00 M |
$0.00 |
$297,000.00 |
$3.32 M |
$2.30 M |
$4.51 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$65,000.00
|
$472,000.00
|
$0.00
|
$0.00
|
$1.53 M
|
$1.75 M
|
$2.17 M
|
| Gross Profit |
$2.00 M
|
$0.00
|
$232,000.00
|
$2.85 M
|
$2.30 M
|
$4.51 M
|
-$1.53 M
|
-$1.75 M
|
-$2.17 M
|
| Gross Profit Ratio |
1
|
0
|
0.78
|
0.86
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$286,000.00
|
$1.52 M
|
$31.49 M
|
$37.64 M
|
$56.41 M
|
$95.14 M
|
$87.72 M
|
$78.80 M
|
$50.90 M
|
| General & Administrative Expenses |
$5.34 M
|
$8.13 M
|
$14.50 M
|
$20.62 M
|
$28.82 M
|
$34.40 M
|
$27.54 M
|
$15.12 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.34 M
|
$8.13 M
|
$14.50 M
|
$20.62 M
|
$28.82 M
|
$34.40 M
|
$27.54 M
|
$15.12 M
|
$10.48 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.33 M
|
-$622,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.63 M
|
$9.65 M
|
$44.67 M
|
$57.63 M
|
$85.23 M
|
$129.54 M
|
$115.25 M
|
$93.92 M
|
$61.38 M
|
| Cost And Expenses |
$5.63 M
|
$9.65 M
|
$44.67 M
|
$57.63 M
|
$85.23 M
|
$129.54 M
|
$115.25 M
|
$93.92 M
|
$63.55 M
|
| Interest Income |
$208,000.00
|
$358,000.00
|
$294,000.00
|
$0.00
|
$588,000.00
|
$2.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$294,000.00
|
$16,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
-$2.95 M
|
$65,000.00
|
$472,000.00
|
$2.30 M
|
$2.70 M
|
$1.53 M
|
$1.75 M
|
$2.17 M
|
| EBITDA |
-$3.63 M |
-$12.59 M |
-$18.18 M |
-$55.20 M |
-$81.27 M |
-$122.34 M |
-$113.72 M |
-$92.18 M |
-$61.38 M |
| EBITDA Ratio |
-1.81
|
0
|
-149.18
|
-16.22
|
-37.1
|
-27.14
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.81
|
0
|
-149.4
|
-16.63
|
-35.39
|
-27.74
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$571,000.00
|
-$2.95 M
|
$294,000.00
|
$3.55 M
|
$3.46 M
|
$2.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$3.06 M
|
-$12.59 M
|
-$44.08 M
|
-$51.65 M
|
-$77.80 M
|
-$123.01 M
|
-$115.25 M
|
-$93.92 M
|
-$63.55 M
|
| Income Before Tax Ratio |
-1.53
|
0
|
-148.41
|
-15.56
|
-33.89
|
-27.29
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$294,000.00
|
$16,000.00
|
-$5.13 M
|
-$2.03 M
|
$1.37 M
|
$0.00
|
$0.00
|
| Net Income |
-$3.06 M
|
-$21.02 M
|
-$43.78 M
|
-$51.66 M
|
-$72.67 M
|
-$120.98 M
|
-$115.25 M
|
-$93.92 M
|
-$63.55 M
|
| Net Income Ratio |
-1.53
|
0
|
-147.42
|
-15.56
|
-31.65
|
-26.84
|
0
|
0
|
0
|
| EPS |
-1.21 |
-8.99 |
-20.15 |
-26.4 |
-47.8 |
-88.37 |
-84.42 |
-68.8 |
-46.39 |
| EPS Diluted |
-1.21 |
-8.99 |
-20.15 |
-26.4 |
-47.8 |
-88.37 |
-84.42 |
-68.8 |
-46.39 |
| Weighted Average Shares Out |
$2.52 M
|
$2.34 M
|
$2.17 M
|
$1.96 M
|
$1.52 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
| Weighted Average Shares Out Diluted |
$2.52 M
|
$2.34 M
|
$2.17 M
|
$1.96 M
|
$1.52 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
